On Friday, Benitec Biopharma Inc (NASDAQ: BNTC) was -6.24% drop from the session before settling in for the closing price of $12.17. A 52-week range for BNTC has been $2.69 – $13.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -42.37%. When this article was written, the company’s average yearly earnings per share was at 52.64%. With a float of $20.72 million, this company’s outstanding shares have now reached $23.22 million.
Considering the fact that the conglomerate employs 16 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -2933.33%, operating margin of -373500.0%, and the pretax margin is -347600.0%.
Benitec Biopharma Inc (BNTC) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Benitec Biopharma Inc stocks. The insider ownership of Benitec Biopharma Inc is 10.76%, while institutional ownership is 67.39%. The most recent insider transaction that took place on Dec 03 ’24, was worth 403,200. In this transaction Director of this company bought 42,000 shares at a rate of $9.60, taking the stock ownership to the 7,957,365 shares. Before that another transaction happened on Nov 20 ’24, when Company’s Director bought 27,436 for $10.22, making the entire transaction worth $280,396. This insider now owns 7,920,175 shares in total.
Benitec Biopharma Inc (BNTC) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.64% per share during the next fiscal year.
Benitec Biopharma Inc (NASDAQ: BNTC) Trading Performance Indicators
You can see what Benitec Biopharma Inc (BNTC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 15.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.28, a number that is poised to hit -0.78 in the next quarter and is forecasted to reach -4.15 in one year’s time.
Technical Analysis of Benitec Biopharma Inc (BNTC)
Compared to the last year’s volume of 48541.0, its volume of 0.17 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 40.55%. Additionally, its Average True Range was 0.94.
During the past 100 days, Benitec Biopharma Inc’s (BNTC) raw stochastic average was set at 69.87%, which indicates a significant increase from 50.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 102.61% in the past 14 days, which was higher than the 74.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.81, while its 200-day Moving Average is $8.66. Nevertheless, the first resistance level for the watch stands at $12.07 in the near term. At $12.73, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.06. If the price goes on to break the first support level at $11.08, it is likely to go to the next support level at $10.75. Should the price break the second support level, the third support level stands at $10.09.
Benitec Biopharma Inc (NASDAQ: BNTC) Key Stats
There are 23,216K outstanding shares of the company, which has a market capitalization of 264.94 million. As of now, sales total 0 K while income totals -21,750 K. Its latest quarter income was 0 K while its last quarter net income were -5,060 K.
